SCHEMBL1070738

SCHEMBL1070738

CCCCCC(CCCC)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.74
MAPK1 P28482 1/20 0.74
GRIK1 P39086 2/20 0.64
GRIK2 Q13002 2/20 0.64
SLC1A2 P43004 2/20 0.64
SLC1A1 P43005 2/20 0.64
CHRM1 P11229 1/20 0.64
AKR1A1 P14550 1/20 0.64
CHRM3 P20309 1/20 0.64
HTR2A P28223 1/20 0.64
HTR2C P28335 1/20 0.64
ADRA1A P35348 1/20 0.64
HRH1 P35367 1/20 0.64
DRD3 P35462 1/20 0.64
SLC6A3 Q01959 1/20 0.64
HDAC1 Q13547 1/20 0.64
HDAC2 Q92769 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
SLC1A3 P43003 1/20 0.61
GPR84 Q9NQS5 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL538817 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL1310131 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL1457282 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL5683424 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL9118821 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL112564 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL2492298 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL112082 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL2836840 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL160269 0.98 CA2 (0.71) CA2MAPK1GRIK1GRIK2SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679908-B Organic compounds GIVAUDAN SA 2012-10-24 CN claimed
CN-102459278-A Substituted-1, 3, 8-triazaspiro [4.5] decane-2, 4-diones MERCK SHARP & DOHME 2012-05-16 CN claimed
EP-1716159-B1 BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS MOMENTIVE PERFORMANCE MAT INC (US) 2011-07-13 EP claimed
CN-101679908-A organic compounds GIVAUDAN SA 2010-03-24 CN claimed
EP-1697386-B1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES GEN ELECTRIC (US) 2007-10-10 EP claimed
EP-1328161-B1 AMBIENT STABLE BEVERAGE UNILEVER PLC (GB) 2007-04-18 EP claimed
EP-1282368-B1 AMBIENT STABLE BEVERAGE UNILEVER PLC (GB) 2005-07-27 EP claimed
US-20260137803-A1 LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF GENZYME CORP (US) 2026-05-21 US disclosed
US-12564879-B2 Copper paste for joining, method for manufacturing joined body, and joined body RESONAC CORPORATION (JP) 2026-03-03 US disclosed
US-20260028721-A1 METHOD FOR MANUFACTURING SUBSTRATE WITH CONDUCTIVE VIAS AND METHOD FOR MANUFACTURING WIRING BOARD WITH CONDUCTIVE VIAS RESONAC CORP (JP) 2026-01-29 US disclosed
US-20250387833-A1 METHOD FOR MANUFACTURING CONDUCTIVE VIA-CONTAINING SUBSTRATE, CONDUCTIVE VIA-CONTAINING SUBSTRATE, AND METAL PASTE RESONAC CORP (JP) 2025-12-25 US disclosed
EP-4658313-A1 HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF GENZYME CORPORATION (US) 2025-12-10 EP disclosed
US-20250293091-A1 METHOD FOR PRODUCING SUBSTRATE HAVING THROUGH-SILICON VIAS, SUBSTRATE HAVING THROUGH-SILICON VIAS, AND COPPER PASTE FOR THROUGH-SILICON VIA FORMATION RESONAC CORPORATION (JP) 2025-09-18 US disclosed
WO-1995018616-A2 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR ACEA PHARM INC (US) 1995-07-13 WO disclosed
EP-0647137-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-04-12 EP disclosed
WO-1994000124-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF WEBER ECKARD (US) 1994-01-06 WO disclosed
US-5252432-A Developing the recoding layer with developer 3-methoxy-butyl acetate or/and butyl glycolate BASF AKTIENGESELLSCHAFT (DE) 1993-10-12 US disclosed
US-5240815-A Exposing photopolymerizable component to actinic light, development BASF AKTIENGESELLSCHAFT (DE) 1993-08-31 US disclosed
US-5128234-A PRODUCTION OF PHOTOPOLYMERIC FLEXOGRAPHIC RELIEF PRINTING PLATES BASF AKTIENGESELLSCHAFT (DE) 1992-07-07 US disclosed
US-5080889-A Oil, oxidation resistance, stability KAO CORPORATION (JP) 1992-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387833-A1 METHOD FOR MANUFACTURING CONDUCTIVE VIA-CONTAINING SUBSTRATE, CONDUCTIVE VIA-CONTAINING SUBSTRATE, AND METAL PASTE C5, C9, CUTA CA2 2282/4885MAPK1 210/4885GRIK1 1331/4885
US-20260028721-A1 METHOD FOR MANUFACTURING SUBSTRATE WITH CONDUCTIVE VIAS AND METHOD FOR MANUFACTURING WIRING BOARD WITH CONDUCTIVE VIAS PIEZO1, CACNA1C, GJB2 CA2 1511/4885MAPK1 86/4885GRIK1 812/4885
US-12564879-B2 Copper paste for joining, method for manufacturing joined body, and joined body DCX, DNAJA2, DNAJA1 CA2 4461/4885MAPK1 3048/4885GRIK1 2953/4885
US-20260137803-A1 LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF CD2BP2, CD2, CD4 CA2 1782/4885MAPK1 3564/4885GRIK1 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.